Bulls v Bears

Since MMJ and the industry itself is on the cusp of a major paradigm shift, I feel it's time to thrash out the arguments for the MMJ bears and the MMJ bulls out there for April 2017.

MMJ Bulls
* "Satipharm is currently preparing a significant marketing campaign to drive sales of 10 MG and 50 MG capsules commencing October focusing first on Germany and Poland followed by entry into 10 additional EU countries in April 2017" (AGM Presentation).  Ten additional countries this month.
* "Satipharm has developed the ‘first and only’ product on the market with a pharmaceutical grade GMP (Good Manufacturing Product) production – unique GelPellⓇ Microgel Capsules" (Investor Presentation).  Who else can lay claim to that?
* Clinical trials for PTL101 and PTL201 have commenced. Conclusion scheduled for late 2017.
* "Duncan Facility cultivation to include simultaneous growing of multiple unique cannabis strains that previously have not been available to Canadian consumers" (AGM Presentation).  Thirty three strains available for the MC and recreational market.
* First harvest announced and has passed internal QC according to licensing conditions.
* HL Pharma has received a license to import and MMJ has a binding LOI with HL Pharma.
* Major changes to proposed Canadian recreational legislation on Monday 10th.  Expectation that the ASX will react on Tuesday 11th.
* "TSX-V listing expected to mitigate MMJ’s prolonged trading valuation discount by providing direct access to robust Canadian capital markets" (Investor Presentation).  The TSX listing should unite MMJ and WON share prices.
* Potential EFT interest if recreational legislation is passed.
* Renewed enthusiasm for MMJ when Harvest One lists.
* MMJ holders will not be hit with another CR needed for expansion.
* Large funds have an interest.
* No record of directors selling (yet) in 2017.

MMJ Bears
* Canadian recreational legislation yet to be passed (not a fait accompli).
* MMJ relinquished ~30% of their most lucrative assets.
* Delays in the TSX listing that potentially should stave off MMJ's current SP volatility.
* Clinical trials yet to be open for recruitment (as per the https://clinicaltrials.gov/ct2/home website).
* HL Pharma has the import permit but that doesn't include the GelPell product as yet.
* Lacklustre Gelpell sales to date in the EU.
* No announcement regarding Fresh Therapeutics.
* 100% owned Therapeutics don't seem to be moving with its buccal cheek patch or Canigma investment.
* No new change in substantial holdings announcements.  Large funds aren't jumping in yet and increasing their holdings.
* Investor fatigue across the whole sector.
* No record of directors buying (yet) in 2017.

For more information (although a little dated):
http://clients3.weblink.com.au/pdf/MMJ/01783237.pdf
http://clients3.weblink.com.au/pdf/MMJ/01806939.pdf

Apologies for any errors or omissions, but feel free to add.